Serum β2—Microglobulin Levels in Patients with Various Solid Cancer

Kesheng Li1*, Huifeng Du1, Xiaowen Lian1, Ming Yuan1, Qinjiang Liu2, Suisheng Yang2, Xuezhong Chen1, Rong Yang3 and Wenhua Ye1

1Department of Medicine Biotechnology, Medicine and Science Research Institute of Gansu province, Lanzhou, China
2Department of Nosecone and Carotid Surgery, Tumor Hospital of Gansu province, Lanzhou, China
3Department of Breast Surgery, Tumor Hospital of Gansu province, Lanzhou, China

Abstract

Background: The level of β2-M has become one of the most important prognostic factors and predictors of survival in patients with certain cancer. The aim of this study was to investigate the serum levels of β2-M in patients with various solid cancers, to find the prognostic and predictive value of serum β2-M level elevating in patients with solid cancer.

Methods: A total of 1158 serum samples from 774 patients with various solid cancer and 384 patients with various solid benign tumor patients were analyzed by β2-microglobulin ELISA kit, the data were analyzed by using statistical 36 packages for sciences (spss11.0) software.

Results: In patients with thyroid cancer, patients with breast cancer and that with liver cancer the mean β2-microglobulin levels and positive rate were significantly higher than that in controls (p<0.05, p<0.01). In patients with other solid cancer including gastric, esophagus, intestinal and lung cancer the mean β2-microglobulin levels have no significant difference compared with that in controls (p>0.05), and the positive rats were not significantly different compared with that in controls (p>0.05) except the patients with esophagus cancer in which the positive rate was significantly different compared with that in controls (p<0.01). In female breast cancer patients the mean β2-microglobulin levels and the positive rate were significantly higher than that in breast benign tumor patients (p<0.05, p<0.05), no significant difference stages and clinical stages. In thyroid cancer patients the mean β2-microglobulin levels and the positive rate were significantly higher than that in thyroid benign tumor patients (p<0.05, p<0.01), no significant difference in sex, ages, clinical stages, but the mean β2-microglobulin levels and the positive rate were significantly higher in patients with follicular thyroid cancer than that in patients with mamillary thyroid 54 cancer patients.

Conclusion: β2-M is an important tumor marker in breast, thyroid and liver cancer that would be one of assistant diagnostic factors in patients with these cancers.

Introduction

β2-microglobulin is a low molecular weight protein consisting of a single chain of 100 amino acids which is part of the HLA antigen molecule, where it represents the invariant light chain [1,2]. It is expressed on the membrane of almost all nucleated cells, and is detectable in all body fluids as a shedding product of cell membrane [3]. Approximately 50% β2-M is produced by lymphocytes and is filtered freely over the glomerulus. Under normal circumstances, more than 99.9% is reabsorbed in the proximal tubuli of the kidneys and metabolized there. In renal disease with damage to this segment of the nephro, eg. Acute tubuli, increased quantities of β2-M are excreted in the urine. If the rate of glomerular filtration is reduced, serum β2-M is increased and this is also the case in persons with increased cell division despite normal renal function [4]. Therefore, the serum and urine β2-M concentrations are used to monitor glomerular and tubular nephropathies [5], and its level is elevated in patients with certain malignancies, including solid and liquid tumors [6,7]. The increased tissues and serum level of β2-M is associated a high 74 tumor burden and poor prognosis. Thus, the level of β2-M has become one of the most important prognostic factors and predictors of survival in patients with certain cancers [7-9]. But, the clinical usefulness of measuring serum β2-M in some solid tumors is controversial in the literature [10,11]. The aim of this study was to investigate the serum levels of β2-M in patients with various solid cancer.

Patients and Methods

A total of 1158 serum samples from 774 patients with various solid cancer and 384 patients with various solid benign tumor who were referred to the Tumor Hospital of Gansu province for treatment, proved by clinical and histopathological evidence, and all patients had normal renal function; 1002 serum from healthy individual who were referred to healthy examination center of Ren Min Hospital of Gansu province for physical examination. The patients characteristics and healthy controls are listed in Table 1.

Under aseptic precautions venous blood was drawn preoperatively and serum was separated. The samples were frozen at -20°C until assay. The serum was analyzed by Enzyme Linked Immunosorbent Assay (β2-microglobulin ELISA kit, developed by Department of Medicine Biotechnology, Medicine and Science Research Institute of Gansu province). The data were analyzed by using statistical package for sciences (spss11.0) software, p<0.05 were considered significant.

Results

Mean levels of serum β2-microglobulin in solid cancer patients

In order to get mean β2-microglobulin levels in healthy individual
to be used as controls and the 2 times mean β2-microglobulin levels in controls was used as cut off. The mean levels of serum β2-microglobulin and the positive rate in patients with various solid cancer and controls are given in Table 2. In patients with thyroid, breast and liver cancer the mean β2-microglobulin levels and the positive rate were significantly higher than that in controls (p<0.05, figure 1A; p<0.01, figure 1B). In patients with other solid cancer including gastric, esophagus, intestinal and lung cancer the mean β2-microglobulin levels and the positive rats have no significant difference compared with that in controls (p >0.05,figure 1A; p > 0.05; figure 1B), except the esophagus cancer patients in which the positive rate was significantly different compared with that in control (p<0.01; figure 1B).

Mean levels of serum β2-microglobulin in female patients with breast cancer and breast benign tumor

<table>
<thead>
<tr>
<th>Group</th>
<th>No</th>
<th>sex</th>
<th>ranges(years)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td>1002</td>
<td>Men</td>
<td>559 - 443</td>
</tr>
<tr>
<td>Thyroid Ca.</td>
<td>95</td>
<td>Women</td>
<td>26 - 69</td>
</tr>
<tr>
<td>Thyroid benign-tumors.</td>
<td>243</td>
<td></td>
<td>54 - 189</td>
</tr>
<tr>
<td>Breast Ca.</td>
<td>205</td>
<td></td>
<td>4 - 201</td>
</tr>
<tr>
<td>Breast benign-tumors.</td>
<td>141</td>
<td></td>
<td>6 - 135</td>
</tr>
<tr>
<td>Liver Ca.</td>
<td>77</td>
<td></td>
<td>57 - 20</td>
</tr>
<tr>
<td>Gastric Ca.</td>
<td>148</td>
<td></td>
<td>114 - 34</td>
</tr>
<tr>
<td>Esophagus Ca.</td>
<td>72</td>
<td></td>
<td>64 - 8</td>
</tr>
<tr>
<td>Intestinal Ca.</td>
<td>58</td>
<td></td>
<td>42 - 16</td>
</tr>
<tr>
<td>LungCa.</td>
<td>119</td>
<td></td>
<td>78 - 41</td>
</tr>
</tbody>
</table>

**Table 1:** Patients characteristics and healthy controls.

The mean β2-microglobulin levels and the positive rats in female patients with breast cancer and breast 112 benign tumor were analyzed, the 2 times mean β2-microglobulin levels in control were used as its cut off. The results were showed in table 3. In female patients with breast cancer the mean β2-microglobulin levels and the positive rate were significantly higher than that in control and patients with breast benign tumor (p<0.05 figure 2A, p<0.05; figure 2B). In patients with breast benign tumor the mean β2-microglobulin level has no significant difference compared with that in control, but the positive rate was significantly higher than that in control (p>0.05 figure 2A: p>0.05, figure 2B). In female patients with breast cancer the mean β2-microglobulin levels have no significant difference at ages and clinical stages, but the positive rate in ages of ≥60 years was significantly lower than that in ages of < 60 years (p<0.01).

**Mean levels of serum β2-microglobulin in patients with thyroid cancer and thyroid benign tumor**

The mean β2-microglobulin levels in patients with thyroid cancer and thyroid benign tumor were analyzed, the 2 times mean β2-microglobulin level in controls was used as its cut off, and the results were showed in table 3. In patients with thyroid cancer the mean β2-microglobulin levels and the positive rate were significantly higher than that in control and patients with thyroid benign tumor (p<0.05, p<0.01; figure 2C,D). The mean β2-microglobulin levels and the positive rate have no significant difference between controls and patients with thyroid benign tumor (p>0.05, p>0.05: figure 2C,D). In patients with thyroid cancer the mean β2-microglobulin levels and the positive rate have no significant difference in clinical stages I-III (p> 0.05, p>0.05) but having significant difference in clinical

**Table 2:** Mean levels of serum β2-microglobulin in Patients with various solid Cancer and controls.

<table>
<thead>
<tr>
<th>Group</th>
<th>No</th>
<th>Serum β2-M (mg/L)</th>
<th>%</th>
<th>%</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Controls</td>
<td>1002</td>
<td>0.99±4.47</td>
<td>7.88</td>
<td>0.01</td>
<td></td>
</tr>
<tr>
<td>Thyroid Ca.</td>
<td>95</td>
<td>2.84±4.56</td>
<td>&lt;0.05</td>
<td>0.01</td>
<td>34.73</td>
</tr>
<tr>
<td>Breast Ca.</td>
<td>205</td>
<td>2.02±4.78</td>
<td>&lt;0.05</td>
<td>0.01</td>
<td>28.29</td>
</tr>
<tr>
<td>Liver Ca.</td>
<td>77</td>
<td>2.81±6.16</td>
<td>&lt;0.05</td>
<td>0.01</td>
<td>23.37</td>
</tr>
<tr>
<td>Gastric Ca.</td>
<td>148</td>
<td>1.25±3.24</td>
<td>&lt;0.05</td>
<td>0.01</td>
<td>11.98</td>
</tr>
<tr>
<td>Esophagus Ca.</td>
<td>72</td>
<td>1.47±3.20</td>
<td>&lt;0.05</td>
<td>0.01</td>
<td>18.05</td>
</tr>
<tr>
<td>Intestinal Ca.</td>
<td>58</td>
<td>1.51±4.71</td>
<td>&lt;0.05</td>
<td>0.01</td>
<td>13.79</td>
</tr>
<tr>
<td>LungCa.</td>
<td>119</td>
<td>0.94±2.03</td>
<td>&lt;0.05</td>
<td>0.01</td>
<td>11.76</td>
</tr>
</tbody>
</table>

**Figure 1:** Mean level and positive rate of serum β2-microglobulin in Patients with various solid Cancer and controls. A. mean level of serum β2-microglobulin, 1. Thyroid Ca., 2. Breast Ca., 3. Liver Ca., 4. Gastric Ca., 5. Esophagus Ca., 6. Intestinal Ca., 7. Lung Ca., 8. Controls. B. positive rate of serum β2-microglobulin, 1. Thyroid Ca., 2. Breast Ca., 3. Liver Ca., 4. Gastric Ca., 5. Esophagus Ca., 6. Intestinal Ca., 7. Lung Ca., 8. Controls. VI p<0.01.

**Figure 2:** Mean level and positive rate of serum β2-microglobulin in female patients with breast cancer and breast benign tumor, patients with thyroid cancer and thyroid benign tumor. A. mean level of serum β2-microglobulin in patients with breast cancer, 1. female patients with breast cancer, 2. female patients with breast benign tumor. B. positive rate of serum β2-microglobulin in patients with breast cancer, 1. female patients with breast cancer, 2. female patients with breast benign tumor. C. Mean level of serum β2-microglobulin in patients with thyroid cancer, 1. patients with thyroid cancer, 2. patients with thyroid benign tumor. D. positive rate of serum β2-microglobulin in patients with thyroid cancer, 1. patients with thyroid cancer, 2. patients with thyroid benign tumor. VI p<0.01.
The results demonstrate that serum β2-microglobulin may be valuable marker in the diagnosis of breast cancer, thyroid cancer, liver cancer and esophagus cancer, but as an independent tumor marker, the clinical valuation of serum level elevating of β2-microglobulin in the diagnosis of gastric cancer, intestinal cancer and lung cancer seems limited, agreeing with the literature [11,12,14].

In order to avoid false positive results and decide the reliable cut off level, the serum level changing of β2-microglobulin of healthy individuals 167 during at different ages and sex were analyzed, the results showed that the β2-M level in healthy individuals have no significant difference in sex and age except the females of ≤ 40 years in whom the β2-M level was significantly lower than that of >40 years, suggesting that when evaluated the β2-M level was used to elevate the positive rate in female patients with cancer, the individual cut off levels was needed.

In female patients with breast cancer the mean β2-microglobulin levels and positive rate have no significant difference at ages, clinical stages and cell type, but the positive was highest in patients of ≤ 40 years, suggesting that detecting serum β2-microglobulin level in patients of ≤ 40 years may have more clinical valuation than that in the patients of > 40 years.

In patients with thyroid cancer the mean β2-microglobulin levels......
and positive rate have no significant difference at sex, age and clinical stages but positive was highest in patients in range 40-60 years, and in patients with folliculare thyroid cancer the mean β2-microglobulin levels and the positive rate were significantly higher than that in patients with mammillary thyroid cancer, suggesting that detecting serum β2-microglobulin level in range 40-60 years may have more clinical valuation than that in the patients of 18<40 years and ≥60 years, and more sensitive in folliculare thyroid cancer than in other cell type.

Another observation that emerged from the current study is the serum levels elevating of β2-M have no significant diagnostic valuation in thyroid cancer and breast cancer patients of ≥60 years. These observation are not in line with previous report showing that the serum β2-M levels have independent prognostic role in patients with AML who are ≥60 years old [7]. This observation may be explained that the serum β2-M levels elevated in normal individual of ≥60 years under normal physiological condition may be due to the β2-M metabolizing decreasing. Therefore, the serum β2-M level elevating in patients of ≥60 years has no significant difference compared with normal individual.

The mechanism of altered β2-M level is not yet clearly understood. Various Possibilities for increased serum level of β2-M suggested are an increased cellular activity in malignancy being responsible for an increased release of β2-M, β2-M being a constituent of HLA molecules, cell membrane turnover or cell division could increased the shedding of β2-M [16], β2-M and HLA molecules variably expressed on the surface of tumor cells [17-23]. Because the HLA class I antigen 203 are key component of the immune system, the recognition of tumor-specific antigen by cytotoxic T cell is dependent on intact HLA expression. Malignant cells with modified or lacking of HLA expression may escape from the normal host immune response and proliferate uncontrollably [24-26]. A structural defect of the HLA complex may also result in changes in epitope expression and increased release of β2-M in serum [27-30]. This mechanism is consistent with the observation that serum β2-M levels reflect tumor burden and cell turnover [27,28,31,32]. This mechanism also can explain why the mean β2-microglobulin levels in patients with breast, thyroid and liver cancer were significantly higher than that in patients with benign tumor in present study, the reason may be that the cancer cell burden and turnover more quickly than benign tumor.

We cannot explained the reason why the mean elevated β2-microglobulin level significantly higher in patients with breast, thyroid and liver cancer than that in patients with other solid cancer, but we noted that the breast cancer and thyroid cancer have same feature that the breast cancer and thyroid cancer both are glandular cancer and both are correlated with the estrogen receptor (ER), progesterone receptor (PR) and HER2/neu [33,34]. Whether β2-microglobulin have any correlation with the ER, PR and HER2/neu in breast and thyroid cancer need further studying.

The another possibility of the mechanism responsible for an increase in β2-M expression during the progression of cancer is that the tumors contain three β2-M alleles instead of one. Recently, Nomura et al.[36] demonstrated that promoted growth of β2-M in human renal cell carcinomas while interrupting the β2-M signaling pathway lead to apoptosis of tumor cells Huang et al. [37] reported that β2-M is a signaling and growth promoting factor for human prostate cancer bone metastasis, β2-M stimulate growth and enhance osteocalcin(OC) and bone sialoprotein (BSPI) gene expression in human prostate cancer cells by activating cyclic AMP(CAMP)-dependent protein kinase A signaling pathway Chen et al. [35] reported that β2-M may act as an effective growth promoting factor to facilitate tumor progression, invasion, and migration in oral cavity squamous cell carcinoma. Yang et al. [38] discovered that monoclonal antibodies (mAbs) specific to human β2-M induce apoptosis in vitro and were therapeutic in mouse models of myeloma and other hematological tumor cells via recruiting MHC class I molecules to lipid rafts and activating Lyn and PLCγ2, leading to activated JNK and inhibited P13K/Akt and ERK, compromised mitochondrial integrity, and caspase-9-dependent cascade activation [38]. Accordingly, these finding address 241 that β2-M must play a far-reaching function than just a housekeeping gene or role on stabilization and presentation of MHC class I molecule in cells, an elevated serum β2-M may become one of important diagnosis factor, prognostic factor and survival predictors. The correlation of β2-M with Development, progression and differentiation of tumor need further studying.

In conclusion, we found that the serum elevated level of β2-microglobulin in patients with breasts cancer, thyroid cancer and liver cancer have been observed to be significantly higher than that in the controls, suggesting that β2-M is an important tumor marker in breast, thyroid and liver cancer that would be one of important assistantly diagnostic factors in patients with these cancer.

Acknowledgements
This work was supported by grants of Natural Science Foundation of China (81060247).

References


This article was originally published in a special issue, Cancer Biomarkers handled by Editor(s). Dr. Sudhir Srivastava, Cancer Biomarkers Research Group, National Institute of Health, USA; Dr. Shou-Jiang Gao, The University of Texas Health Science Centre at San Antonio, USA; Dr. Kenneth Moiese, University of Medicine & Dentistry of New Jersey, New Jersey Medical School, USA